transparent gif


Ej inloggad.

Göteborgs universitets publikationer

One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial

Författare och institution:
M. C. Bunck (-); M. Diamant (-); A. Corner (-); Björn Eliasson (Institutionen för medicin); J. L. Malloy (-); R. M. Shaginian (-); W. Deng (-); D. M. Kendall (-); M. R. Taskinen (-); Ulf Smith (Institutionen för medicin, avdelningen för molekylär och klinisk medicin); H. Yki-Jarvinen (-); R. J. Heine (-)
Publicerad i:
Diabetes Care, 32 ( 5 ) s. 762-8
1935-5548 (Electronic)
Artikel, refereegranskad vetenskaplig
Sammanfattning (abstract):
OBJECTIVE: Traditional blood glucose-lowering agents do not sustain adequate glycemic control in most type 2 diabetic patients. Preclinical studies with exenatide have suggested sustained improvements in beta-cell function. We investigated the effects of 52 weeks of treatment with exenatide or insulin glargine followed by an off-drug period on hyperglycemic clamp-derived measures of beta-cell function, glycemic control, and body weight. RESEARCH DESIGN AND METHODS: Sixty-nine metformin-treated patients with type 2 diabetes were randomly assigned to exenatide (n = 36) or insulin glargine (n = 33). beta-Cell function was measured during an arginine-stimulated hyperglycemic clamp at week 0, at week 52, and after a 4-week off-drug period. Additional end points included effects on glycemic control, body weight, and safety. RESULTS: Treatment-induced change in combined glucose- and arginine-stimulated C-peptide secretion was 2.46-fold (95% CI 2.09-2.90, P < 0.0001) greater after a 52-week exenatide treatment compared with insulin glargine treatment. Both exenatide and insulin glargine reduced A1C similarly: -0.8 +/- 0.1 and -0.7 +/- 0.2%, respectively (P = 0.55). Exenatide reduced body weight compared with insulin glargine (difference -4.6 kg, P < 0.0001). beta-Cell function measures returned to pretreatment values in both groups after a 4-week off-drug period. A1C and body weight rose to pretreatment values 12 weeks after discontinuation of either exenatide or insulin glargine therapy. CONCLUSIONS: Exenatide significantly improves beta-cell function during 1 year of treatment compared with titrated insulin glargine. After cessation of both exenatide and insulin glargine therapy, beta-cell function and glycemic control returned to pretreatment values, suggesting that ongoing treatment is necessary to maintain the beneficial effects of either therapy.
Ämne (baseras på Högskoleverkets indelning av forskningsämnen):
Arginine/pharmacology, Blood Glucose/metabolism, Body Mass Index, C-Peptide/blood, Diabetes Mellitus, Type 2/blood/*drug therapy/physiopathology, Female, Hemoglobin A, Glycosylated/metabolism, Humans, Hypoglycemic Agents/*therapeutic use, Insulin/*analogs & derivatives/*secretion/therapeutic use, Insulin-Secreting Cells/drug effects/*physiology, Kinetics, Male, Metformin/*therapeutic use, Middle Aged, Peptides/*therapeutic use, Venoms/*therapeutic use
Postens nummer:
Posten skapad:
2009-12-08 12:53
Posten ändrad:
2011-01-20 09:59

Visa i Endnote-format

Göteborgs universitet • Tel. 031-786 0000
© Göteborgs universitet 2007